REM sleep behaviour disorder in patients without synucleinopathy

Keir, Lindsay H. M.; Breen, David P.

doi:10.1136/jnnp-2020-323475

Cited by 13 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RBD can also be associated with a number of other pathologies such as beta-amyloid, tau, and TDP-43, as well as structural lesions and autoimmune diseases. 21 Thus, despite its high prevalence in PD, the inconsistent disease specificity and the overlap between "brainfirst 00 and "body-first" cohorts make RBD a problematic anchor of the "body-first" onset-based subtype.…”

Section: Rbd As the Feature Distinguishing Between Subtypesmentioning

confidence: 99%

“…Moreover, while approximately 70% of patients with RBD will develop a synucleinopathy when followed over a period of 12 years, 20 a significant proportion will not. RBD can also be associated with a number of other pathologies such as beta‐amyloid, tau, and TDP‐43, as well as structural lesions and autoimmune diseases 21 . Thus, despite its high prevalence in PD, the inconsistent disease specificity and the overlap between “brain‐first″and “body‐first” cohorts make RBD a problematic anchor of the “body‐first” onset‐based subtype.…”

Section: Rbd As the Feature Distinguishing Between Subtypesmentioning

confidence: 99%

See 1 more Smart Citation

The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes

2021

View full text Add to dashboard Cite

Section: Rbd As the Feature Distinguishing Between Subtypesmentioning

confidence: 99%

Section: Rbd As the Feature Distinguishing Between Subtypesmentioning

confidence: 99%

The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes

2021

View full text Add to dashboard Cite

“…On the other hand, RBD is usually diagnosed and managed clinically in most practice settings. It is also now beginning to be recognized that RBD occurs not only in PD, DLB and MSA, but has also been polysomnographically-confirmed in cases of pathologically-proven non-synucleinopathy disorders, including PSP [25].…”

Section: Discussionmentioning

confidence: 99%

Prospective Characterization of Progressive Supranuclear Palsy in a Multi-Ethnic Asian Cohort

Lim

Closas

Tan

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Progressive supranuclear palsy (PSP) is a rare, disabling, neurodegenerative disease. There are limited studies on the spectrum of PSP predominance-types and their clinico-demographic features among Asian patients. We prospectively characterized the clinical features, disease severity, and caregiver burden in a multi-ethnic Asian PSP cohort. Methods: Consecutively-recruited patients with PSP (n=104, 64.4% male; 67.3% Chinese, 21.2% Indians, 9.6% Malays) were extensively phenotyped by a movement disorders neurologist using the MDS-PSP clinical diagnostic criteria and PSP-Clinical Deficits Scale (PSP-CDS). Caregiver burden was measured using the modified Zarit Burden Interview (ZBI). Investigations were reviewed to help rule out potential PSP mimics. Results: There were 104 patients, consisting of 48.1% Richardson syndrome (PSP-RS), 37.5% parkinsonian phenotype (PSP-P), and 10.6% progressive gait freezing phenotype (PSP-PGF). Mean age at motor onset was 66.3 ± 7.7 years, with no significant differences between the PSP phenotypes. Interestingly, REM-sleep behaviour disorder (RBD) symptoms and visual hallucinations (considered rare in PSP) were reported in 23.5% and 22.8% of patients, respectively, and a family history of possible neurodegenerative or movement disorder in 20.4%. PSP-CDS scores were highest (worst) in PSP-RS; and correlated moderately with disease duration (rs=0.45, P<0.001) and weakly with caregiver burden (rs=0.22, P=0.029) in the overall cohort. Three of 48 (6.3%) patients who had whole-exome sequencing harboured pathogenic/likely pathogenic GBA variants. Conclusions: This prospective characterization of a relatively large cohort of Asian PSP patients depicts significant heterogeneity in clinical features and disease burden. Unexpectedly high rates of RBD symptoms, visual hallucinations, and familial involvement warrant further study.

show abstract

“…Tonic and/or phasic muscle twitching, during REM sleep, is seen on video polysomnography (vPSG) alongside (relatively infrequent) dream enactment 73 . RBD occurs in ≈1% of people ≥ 60, 74 but with far higher frequency in LBD. Matar et al 75 .…”

Section: Rem Sleep Behavior Disordermentioning

confidence: 96%

Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions

Townsend

Anderson

Boeve

et al. 2023

Alzheimer's & Dementia

View full text Add to dashboard Cite

In Lewy body dementia (LBD), disturbances of sleep and/or arousal including insomnia, excessive daytime sleepiness, rapid eye movement (REM) sleep behavior disorder, obstructive sleep apnea, and restless leg syndrome are common. These disorders can each exert a significant negative impact on both patient and caregiver quality of life; however, their etiology is poorly understood. Little guidance is available for assessing and managing sleep disorders in LBD, and they remain under‐diagnosed and under‐treated. This review aims to (1) describe the specific sleep disorders which occur in LBD, considering their putative or potential mechanisms; (2) describe the history and diagnostic process for these disorders in LBD; and (3) summarize current evidence for their management in LBD and consider some of the ongoing and unanswered questions in this field and future research directions.

show abstract

REM sleep behaviour disorder in patients without synucleinopathy

Cited by 13 publications

References 6 publications

The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes

The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes

Prospective Characterization of Progressive Supranuclear Palsy in a Multi-Ethnic Asian Cohort

Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions

Contact Info

Product

Resources

About